The Future of Medicine: Exciting New Developments on the Horizon
At the recent 54th meeting of the Advisory Committee on Medicines (ACM) held on December 4-5, 2025, significant discussions took place regarding various premarket registration applications. The committee evaluated a total of ten applications currently under the scrutiny of the Therapeutic Goods Administration (TGA), which are detailed below.
Section A: Premarket Registration Applications
A Closer Look at New and Existing Treatments
The committee reviewed applications that can be categorized into two primary types:
1. New Medicine Applications (Application Type A) – This category includes applications for medicines featuring new active ingredients that have yet to receive approval in Australia.
2. New Indication Applications (Application Type C) – This pertains to established medicines seeking approval for additional therapeutic uses.
Here’s a breakdown of the applications discussed:
New Medicine Applications (Type A)
- apadamtase alfa / cinaxadamtase alfa (ADZYNMA)
- Sponsor: Takeda Pharmaceuticals Australia Pty Ltd
- Therapeutic Area: Congenital thrombotic thrombocytopenic purpura
- Designation: Orphan
cefiderocol sulfate tosilate (FETROJA)
See AlsoSummernats 38 Street Awards: See the Winning Rides!Water Fluoridation & Baby Birth Weight: New Study Reveals Surprising Truth!Nine Issues Apology for Controversial Cartoon: What You Need to KnowMiracle Twins: The Inspiring Story of Conjoined Sisters Abigail and Micaela- Sponsor: Accelagen Pty Ltd
- Therapeutic Area: Antibiotic for adults with limited treatment options
- Sponsor: Accelagen Pty Ltd
seladelpar lysine dihydrate (LIVDELZI)
- Sponsor: Gilead Sciences Pty Ltd
- Therapeutic Area: Primary biliary cholangitis in adults
- Sponsor: Gilead Sciences Pty Ltd
New Indication Applications (Type C)
- Darolutamide (NUBEQA)
- Sponsor: Bayer Australia Ltd
- Therapeutic Area: Metastatic hormone-sensitive prostate cancer
Pembrolizumab (KEYTRUDA)
- Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
- Therapeutic Area: Head and neck squamous cell carcinoma
- Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
lenacapavir sodium (YEYTUO)
- Sponsor: Gilead Sciences Pty Ltd
- Therapeutic Area: HIV pre-exposure prophylaxis in adults
- Priority Designation
- Sponsor: Gilead Sciences Pty Ltd
Buprenorphine (SUBLOCADE MODIFIED RELEASE SOLUTION FOR INJECTION)
- Sponsor: Indivior Pty Ltd
- Therapeutic Area: Opioid dependence
- Sponsor: Indivior Pty Ltd
Guselkumab (TREMFYA)
- Sponsor: Janssen-Cilag Pty Ltd
- Therapeutic Area: Moderate to severe plaque psoriasis in children aged 6 and older
- Sponsor: Janssen-Cilag Pty Ltd
acalabrutinib maleate monohydrate (CALQUENCE)
- Sponsor: AstraZeneca Pty Ltd
- Therapeutic Area: Chronic lymphocytic leukaemia / small lymphocytic lymphoma
- Sponsor: AstraZeneca Pty Ltd
Iptacopan (FABHALTA)
- Sponsor: Novartis Pharmaceuticals Australia Pty Ltd
- Therapeutic Areas: Paroxysmal nocturnal haemoglobinuria and complement 3 glomerulopathy in adults
- Designations: Orphan, Priority
- Sponsor: Novartis Pharmaceuticals Australia Pty Ltd
For those interested in the timelines for evaluating these applications, further details can be accessed through the TGA's official page on Prescription Medicines: Applications Under Evaluation, available at Prescription medicines: Applications under evaluation.
Additionally, the committee provided insights on one nomination for the Medicines Repurposing Program and addressed a general inquiry regarding monitoring requirements for an approved medicine.
For a comprehensive overview of the ACM's discussions and recommendations, more information will likely be disclosed in the Australian Public Assessment Reports (AusPARs), which can be explored at Australian Public Assessment Reports (AusPAR).
Section B: Post-Market Items
Interestingly, the ACM was not called upon to evaluate any post-market or safety concerns during this meeting.
Further Information
To learn more about the Advisory Committee on Medicines, visit the official site at Advisory Committee on Medicines (ACM) or reach out to the ACM Secretary via email at ACM@health.gov.au.
What Are Your Thoughts?
With such crucial developments in the field of medicine, what do you think about the potential impact these new treatments could have on patients? Are there any concerns you feel should be addressed regarding the approval process? Join the conversation and share your opinions!
